Home » Newsletters » BioWorld

BioWorld

Sep. 23, 1992

View Archived Issues

FDA APPROVES GRAFTSKIN EXEMPTION

MBI LICENSES ANTISENSE TO ISIS

PHARMCHEM GETS DRUG TESTING CONTRACT

GENENTECH, UNIVAX TO DEVELOP AIDS DRUG

PDL TESTS HUMANIZED MAB

HYPOGONADISM DRUG ENTERS PHASE III

GENSIA STOCK PLUMMETS ON TRIAL DATA

CHIRON TO REDEEM DEBENTURES

HUNT FOR SCHIZOPHRENIA GENE

CALGENE TO SUPPLY LUBRICANTS

EMBREX LEASES EGG INJECTION SYSTEM

ATRIX BEGINS NEW STUDIES

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....